Intervention

BMS-690514

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions3

Lead sponsors shown1

Clinical trials

3 shown

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior ResponseNCT01167244 · 2010-08-01

COMPLETED

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast CancerNCT01068704 · 2010-06-01

COMPLETED

A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLCNCT00743938 · 2009-03-01

COMPLETED

Common conditions

Breast Cancer1 Non Small Cell Lung Cancer1 Non-Small-Cell Lung Carcinoma1

Leading sponsors

Bristol-Myers Squibb 3

Trial status mix

COMPLETED3

Phase mix

PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.